Country of origin: United States of America, Schering-Plough Labo N.V. Belgium
Pharm-Group: Drugs with glucocorticosteroid activity
Manufacturers: Schering-Plough (United States of America), Schering-Plough Labo N.V. (Belgium)
International name: Beclomethasone
Synonyms: Arumet, Beklazon, Beklazon easy breathing, Beklazon Eco, Beklazon Eco Easy Breathing, Beklat, Beklodzhet 250, Beklokort, Beklomet, Beklomet nasal, Bekloforte, Bekodisk, Beconase, Beconase, Bekotide, Bekotid easy breathing, Bronchoturbinal, Gnadion, Klenil
Dosage forms: aerosol dosed 50mcg, aerosol dosed 50mcg/dose 200dz
Ingredients: Active ingredient - Beclomethasone
Indications for use: Bronchial asthma, chronic obstructive pulmonary diseases, vasomotor rhinitis, recurrent nasal polyposis, allergic rhinitis (seasonal and permanent), juvenile rheumatoid arthritis, inflammatory bowel diseases, dysphonia in systemic lupus erythematosus, persistent inflammation of the middle ear in children, bronchopulmonary dysplasia newborns.
Contraindications: Hypersensitivity, first trimester of pregnancy, breastfeeding. Restrictions on use: Systemic infections, tuberculosis, herpetic eye lesions, II and III trimester of pregnancy.
Side effects: Hoarseness, sore throat, bronchospastic reactions, sneezing attacks, rhinorrhea, feeling of dryness and irritation in the nose, nosebleeds, atrophic rhinitis, ulceration of the nasal mucosa, perforation of the nasal septum, headaches, dizziness, cataracts, increased intraocular pressure, leukocytosis (including neutrophilic), lymphopenia, eosinopenia, manifestations of hypercortisolism, incl. Cushing's syndrome (when using high doses), oropharyngeal candidiasis and aspergillosis, nasal candidiasis, eosinophilic pneumonia, urticaria, angioedema.
Interaction: Increases the effect of beta-agonists, which enhance the anti-inflammatory properties of beclomethasone (increase its penetration into the distal bronchi).
Overdose: Symptoms: hypothalamic-pituitary-adrenal insufficiency. A temporary transfer to systemic glucocorticoids and ACTH are indicated.
Special instructions: Cannot be used to relieve an acute asthmatic attack. If an acute asthma attack develops in response to the use of beclomethasone, it should be discontinued immediately. If there are signs of hypothalamic-pituitary-adrenal insufficiency, inhalations should be continued, but be sure to monitor the level of basal cortisol in the blood plasma. The same monitoring is needed when using high doses of beclomethasone. The transfer of patients with bronchial asthma from systemic glucocorticoids to inhaled forms of beclomethasone dipropionate must be carried out gradually: immediate withdrawal or too rapid dose reduction is unacceptable.
Literature: Encyclopedia of Medicines 2004